Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

Worth noting that the population in the Merck trial were mild to moderate patients, whereas those in the brilacidin trial are moderate to severe. The endpoints are similar.

The Merck trial is a Phase III study.

Also note the sample size:

"At the time of the decision to stop recruitment based on the compelling interim efficacy results, the trial was approaching full recruitment of the Phase 3 sample size of 1,550 patients, with more than 90% of the intended sample size already enrolled."

I still maintain that even with a sicker cohort (which as some longs have noted may be a disadvantage rather than an advantage) in the brilacidin study, 120 patients is not enough to show a statistically significant difference versus placebo, and even if it does, that will not be sufficient to gain an EUA.

https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/